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REVIEW CURRENTOPINION New role of ventricular assist devices as bridge to
transplantation: European perspective1087-2418 Copyright  2017 The Aa bDavid C. Reineke and Paul J. MohacsiPurpose of review
Progress of ventricular assist devices (VAD) technology led to improved survival and apparently low
morbidity. However, from the European perspective, updated analysis of EUROMACS reveals a somewhat
less impressive picture with respect to mortality and morbidity.
Recent findings
We describe the great demand of cardiac allografts versus the lack of donors, which is larger in Europe
than in the United States. Technical progress of VADs made it possible to work out a modern algorithm of
bridge-to-transplant, which is tailored to the need of the particular patient. We analyze the burden of
patients undergoing bridge-to-transplant therapy. They are condemned to an intermediate step, coupled
with additional major surgery and potential adverse events during heart transplantation.
Summary
Based on current registry data, we do have to question the increasingly popular opinion, that the concept
of heart transplantation is futureless, which seems to be for someone who treats and compares both
patients (VAD and heart transplantation) in daily practice, questionable. Up to now, left ventricular assist
device therapy remains a bridge to a better future, which means a bridge to technical innovations or to
overcome the dramatic lack of donors in Europe.
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pre-dominant factor in the treatment of end-stage
heart failure. Especially technical advances in the
field of left ventricular assist devices (LVADs) offer
solutions that are not only about survival but offer
quality of life at the cost of acceptable morbidity on
the waiting list in times of donor scarcity. We will
focus on the new role of bridging a patient to
transplant and try to highlight differences in
approaches between Europe and the United States.
We will discuss the burdens of such a therapy, not
only on the patients but also on relatives. Whether
LVADs will replace organ heart transplantation
(HTx) in the future is uncertain. Today, HTx is the
only reasonable option for transplantable patients.CH-3010 Bern, Switzerland. Tel: +41 31 632 44 64;
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LACK OF DONORS
Two main factors are responsible for organ scarcity
in transplantationmedicine. There is a growing lack
of donors especially in the European countries
because of scepticism towards the organ allocationuthor(s). Published by Wolters Kluweities, and an ever-growing demand of organs
because of patients benefiting from improving
medical systems (Fig. 1). This is especially true in
cardiovascular medicine. While in the last 30 years
coronary death was halved by medical progress,
heart failure has almost tripled with more patients
reaching end-stage heart failure and requiring trans-
plantation [1,2].r Health, Inc. www.co-transplantation.com
KEY POINTS
 Progress of VAD technology is promising, however,
from the European perspective, less impressive with
respect to mortality and morbidity.
 Gap between demand of cardiac allografts and the
lack of donors is larger in Europe than in US.
 A modern algorithm of BTT is tailored to particular
needs of patients.
 There is a significant burden for patients undergoing
BTT therapy for an additional intermediate step of
major surgery and potential adverse events during HTx.
Thoracic transplantationAlthough orthotopic HTx is up to date, the only
curative option in the treatment of end-stage heart
failure, the great imbalance between donors and
patients listed for HTx consequently results in
patients being increasingly treated with mechanical
support devices for bridge to transplant (BTT) [3].MODERN CONCEPT OF BRIDGE TO
TRANSPLANT
The concept of bridging a patient to transplant has
changed in the last years from simply preventing a
patient dying on the waiting list to making him/her
eligible for receiving an organ [bridge to candidacy
(BTC)]. The possibility to offer patients these
options can mostly be put back to the technical
advances moving from first-generation pulsatileFIGURE 1. Imbalance of demand and supply: waiting list is increa
permission from eurotransplant.org—Heart waiting list and transpla
index.php?search_type=transplants&search_organ=&search_regio
search_text=.
226 www.co-transplantation.comflow LVADs to second- and third-generation con-
tinuous flow (CF) devices.TECHNICAL PROGRESS
The change from pulsatile to CF devices has opened
the door to very differentiated treatment concepts.
Miniaturized third-generation ‘hydrodynamic’
(HVAD HeartWare/Medtronic) and fully ‘magneti-
cally’ (SJM/Thoratec, HeartMate 3) levitated flow
technology has enabled minimal invasive implants
placed intrapericardially and via left anterior thor-
acotomy protecting the right ventricle and making
reoperations easier [4].
Newest third-generation devices such as SJM‘s
HeartMate 3 combine CF and an artificial pulse
assisting with pump washing in order to reduce
thrombus related adverse events. This concept of a
‘programmed pulsatility’ might in the long-term
reduce gastric bleeding, aortic valve insufficiency
and peripheral vasoplegia. These factors seem to be
closely related to a pulseless life and increasemorbid-
ity especially in long-term LVAD support [5
&
].
Second and third-generation devices dominate
the market since 2008 with superior outcomes to
their predecessors with survival of 90, 84 and 79% at
6, 12 and 24 months respectively [6]. Well-designed
studies monitor long-term efficacy of two key
devices. ENDURANCE (HVAD) and MOMENTUM
3 (HeartMate 3) will hopefully be able to give
a sound ideas of state of the art device therapy
and further improve their quality adjusted life year
values [7
&&
,8
&&
].singly larger than the number of heart transplants. Reused with
nts, by year-chart. Source: http://statistics.eurotransplant.org/
n=& search_period=by+year+chart&search_characteristic=&
Volume 22  Number 3  June 2017
New role of ventricular assist devices as bridge to transplantation Reineke and MohacsiTAILOR MADE APPROACHES
Because of these incredible advances in device
manufacturing, today bridging a patient to trans-
plantation is about offering tailormade solutions for
defined situations. To preserve end-organ function,
LVADs may even be implanted electively when a
long wait is foreseeable, especially in patients with
blood type 0 [9
&
]. The same goes for patients who are
stable, will need an organ at some stage, but are not
yet eligible for transplant. A good example for this
strategy is cardiorenal syndrome, pulmonary hyper-
tension (PH) or a recently treated malignoma.
Transplantation in patients with presumably
‘fixed’ PH is contraindicated because of the high rate
of right heart failure post-transplantation. It was dem-
onstrated, that LVAD therapy is able to decrease elev-
ated transpulmonary gradients or pulmonary vascular
resistance and successfully overcome this contraindi-
cation for cardiac transplantation. Zimpfer et al. were
able to show a relevant decrease in PH during a six-
week period of support. In view of the high risk of
donor heart failure in patients with ‘fixed’ PH, the
alternative of prior LVAD support and subsequent
orthotropicHTx has proven to be a good concept [10].
This concept is theoretically also applicable to
tumour illnesses in the form of bridge to tumour-
free status. For patients with chemotherapy-induced
DCM technical advances allow device placement
and achievement of tumour-free intervals over a
two to five-year interval prior to HTx [11,12].BRIDGE TO TRANSPLANT IN EUROPE AND
THE UNITED STATES
Because of differences in donor availability and
allocation process the relationship and approach
towards implanting VADs as BTT is different in
the United States and Europe. Although 1-year sur-
vival has considerably improved, current UNOS
policy is still based on the experience with first-
generation assist devices, which in general were able
to only provide reliable support for 1 year. LVAD
patients are automatically given 1B status and are
allowed a 30-day 1A period to avoid device compli-
cations. This is of course questionable in light of
near 90% survival in the current BTT patients [13].
In Europe, on the other hand, stable heart failure
patients on device support are not prioritized.
This has led to a diametric development in the
lives of BTT patients on both continents. While the
concept of BTT has more than halved the rate of
patients dying on the waiting list in Europe and
America [14] the fate of these patients is completely
different. As reported in the 7th INTERMACS annual
report, in America about 60% of donor hearts now
go to patients with LVADs on the waiting list due to1087-2418 Copyright  2017 The Author(s). Published by Wolters Kluweearly automatic prioritization [15
&&
]. This is not the
case in Europe. In 2015, Germany transplanted 82%
of the patients in high urgency category. As only
device complications are prioritized in Germany,
waiting lists of patients on LVAD support are on
the increase [16]. So in reality, in Germany, the
decision to implant an LVAD very nearly equals
the concept of destination therapy (DT).FATE OF BRIDGE TO TRANSPLANT
PATIENTS
Although VAD patients have a substantial improve-
ment in activities and quality of life, they do not
reach levels generally achieved after HTx. Despite of
LVADsupport, 12%ofpatientsdieon thewaiting list.
After 2 years, 30% have become ineligible for an HTx
because of disabling stroke from embolic or intra-
cranial bleeding events, sepsis, progressive kidney or
liver dysfunction. Once any of these conditions
become severe enough to compromise outcome of
HTx, these patients find themself on an unidentified
pathway they did not consent to [9
&
,17].
While at first glance abbreviations like BTT or
DT seem to have a semantic character, the endorse-
ment to one of those acronyms has in reality forced
clinicians into the practice of stating their intention
of therapy and strategy at the time of implant. In
order to avoid these polarizing decisions a ‘no clear
intent’ strategy in the form of a ‘BTC’ has become a
third option.
Implant strategies change all the time or as Fang
et al. nicely pointed out in an editorial on an article
on VAD strategies ‘that an inherent limitation of
such an approach is the attempt to predict the
future’. In his study, Teuteberg et al. focus on the
practice of formulating intent strategy at the time of
LVAD implant. They show that intended strategies
change over time, limiting the usefulness of these
plans. In this study, among 2816 primary LVAD
patients, 1060 patients were designated BTT candi-
dates. At 2 years, 43.5% where no longer listed for
transplant [17,18]. More realistic triage to VAD as
lifetime (destination) therapy, rather than to a long
transplant waiting list would encourage patients
and families to more fully embrace and adapt their
lives to enjoy maximal benefit from MCS [9
&
].BURDEN OF BRIDGE TO TRANSPLANT
THERAPY
Psychological issues and the effect on
surrounding relatives
Compared to palliative treatment strategies [19,20],
MCS is an alternative, but expensive treatmentr Health, Inc. www.co-transplantation.com 227
Thoracic transplantationoption for end-stage heart disease. The incidence of
pre-morbid and post-surgical psychiatric disorders,
the use of psychotropic drugs, as well as neurologic
events must be taken into account when evaluating
the indication for an LVAD [21,22] as psychiatric
burden influences compliance and overall outcome.
After discharge of a VAD patient, caregivers are
additionally placed under significant pressure,
which changes over the span of the VAD experience.
Different coping mechanisms are used to deal with
the initial shock and significant burden [23]. How-
ever, partner support seems to be one of the most
significant psychosocial variables that can influence
clinical success after HTx [24]. Since most of the
LVAD patients are waiting for a HTx, the following
psychological predictors [24] might also be applied
for VAD candidates: empathy, partner support
(affective involvement), few demands for emotional
communication (affective expression), self-control,
stress resistance, emotional stability, high frustra-
tion tolerance, low aggression level and younger
age. Interestingly, BTT strategy does not lead to
post-traumatic stress disorder in patients but may
do in their spouses in the long run [25,26].Redo operation
Several reports have focused on post-transplant
survival in patients who were previously treated
with a device. Multi-variate analysis of registry
data suggested that mechanical support is a predic-
tive factor for poor transplant survival [27]. More
recent reports focusing exclusively on long-term
LVAD use as BTT has refuted these observations
[28,29].
For a centre having great experience with all
kinds of redo-surgery including transplantation
after LVAD, it is not understandable why results
should not suffer from a redo situation. Increased
bleeding with post-operative mass transfusions
surely influence the acute function of the right
ventricle and may influence the immune system
with possible rejections in the future. Current
research shows that open-heart surgery for the
placement of VADs in heart failure patients may
be associated with the development of a systemic
inflammatory response syndrome because of
increased oxidative stress leading to clinical com-
plications and organ dysfunction. VADs are thought
to induce high levels of inflammation as a result of
exposure to non-physiological flow conditions or
artificial surfaces. In daily life we witness that capil-
lary leak syndromes after VAD-transplantations pro-
long hemodynamic stabilization and post-operative
course [30,31
&
,32
&
]. Should complicated LVAD
patients comprise the majority of transplant228 www.co-transplantation.compatients in the future, it will only be a matter of
time, when post-transplant survival will suffer.Neurologic dysfunction
Recently reported event rates vary between 9.8 and
40% (0.21 thromboembolic strikes per year and 0.19
haemorrhagic strokes per year). The ReVOLVE trial
revealed neurological dysfunction accounting for
death in 4.3% of patients after a mean time of
145 days within a range of 1–730 days. Stroke of
any kind occurred in 8% of patients during the same
period. The 7th INTERMACS report reported 1.17
neurologic events per 100 patient months for
patients implanted between 2008 and 2011, and
1.71 events for patients implanted between 2012
and 2014. INTERMACS levels did not influence
neurological events significantly.
Comparing third- and second-generation devi-
ces in view of neurologic outcomes, complication
rates were reported as 19% for 0.44 median years
(HeartWare) and 16% for 0.95 median years (Heart-
Mate II) of follow-up [13,15
&&
,32
&
,33–36].Gastrointestinal bleeding
Gastrointestinal bleeding (GIB) is themost common
reason for readmission after implantation of MCS.
Although direct comparison in literature is difficult
because of differences in definitions and reporting,
similar rates of GIB are documented throughout
current literature. ReVOLVE and Slaughter et al.
report comparable event rates per patient year of
14.8, 12.7 and 26%. These results are also in line
with the 7th INTERMACS report. A recent meta-
analysis by Draper et al. which included 17 studies
and 1697 patients reported a pooled incidence rate
of GIB in patients on LVAD of 23%. The prevalence
of GIB was increased in LVAD patients, primarily
because of proximal GI angiodysplastic lesions. Risk
factors included older age and elevated creatinine
[13,36–38].Infections
Infections are a frequent complication. They can
occur because of exposure to invasive therapies,
prolonged hospitalizations and of course, because
of the percutaneous lead. Causes for readmission are
mainly VAD specific complications in the form of
driveline or even hardware infections. Antibiotic
and antifungal therapy in addition to surgical source
control is crucial. Every effort must be made to clear
the infection prior to HTx with its immunosuppres-
sive therapy.
In the ADVANCE BTT trial, which was aimed at
the approval of the HVAD HeartWare as BTT,Volume 22  Number 3  June 2017
New role of ventricular assist devices as bridge to transplantation Reineke and Mohacsidriveline infections and sepsis, occurred in 12 and
11% of patients, respectively. This is numerically
lower than in second-generation device pivotal
trials. In a pooled multi-centre analysis of Stulak
et al. 734 patients with an LVAD where reviewed for
their adverse events. Cumulative risk of percutane-
ous driveline infection at 1, 3 and 5 years was 7, 20
and 29% respectively. Cumulative risk of any infec-
tion for the entire cohort was 17, 33 and 45%, at 1,
3 and 5 years [39,40
&&
].Pump thrombosis
Despite an overall reduction of adverse events over
the last years, the INTERMACS database reported a
six-fold increase in the rates of pump thrombosis in
Heart Mate II patients between 2011 and 2012.
HeartWare investigators also noticed a higher inci-
dence of thrombosis in their device (0.063–
0.08 events/patient year). An investigation found
that most pump thromboses occurred because of
sub-therapeutic warfarin anticoagulation and tak-
ing low-dose aspirin (i.e., 81mg) or no antiplatelet
therapy at all. After additional technical modifi-
cations in the region of the inflow cannula and
stricter management of anticoagulation, device
exchange because of pump thrombosis fell by
greater than 50%. Stulak et al. reported a cumulative
risk of pump thrombus for his entire cohort of 14,
24 and 25%, at 1, 3 and 5 years. In accordance with
the above cited data, pre-2011 data showed a high
overall incidence of thrombosis of 30% and a much
lower rate of 7.6% after change of strategy
[13,41
&&
,42
&&
].EUROMACS VERSUS INTERMACS
The European Registry for Patients with Mechanical
Circulatory Support (EUROMACS) was founded in
2009 to focus on European data. EUROMACS is the
only existing European-based mechanical support
registry for all devices implanted in children and
adults. Other registries like the American counter-
part INTERMACS (Interagency registry on mechan-
ically assisted circulatory support) only register Food
and Drug Administration (FDA)–approved devices
and no paediatric patients. When the first annual
EUROMACS report was presented at the Annual
Meeting of the European Association of Cardio-
Thoracic Surgery authors emphasized that no big
differences could be seen between the continents. In
our view, there are noteworthy differences to men-
tion. While in EUROMACS only 16% patients are
categorized as destination patients it is nearly half of
all implants in INTERMACS. What strikes the atten-
tive reader of both reports is also the outcome.1087-2418 Copyright  2017 The Author(s). Published by Wolters KluweWhile the actuarial survival rate of CF LVADs in
the INTERMACS cohort after 12 and 24months is 80
and 70%, survival in EUROMACS is considerably
lower with 72.5% after one year and 62.8 at 2 years.
Equally interesting is the comparison of causes of
death. While in EUROMACS, the main cause of
death is infection, sepsis and multi-organ failure,
in INTERMACS its neurologic events. Of course this
is in some way like comparing apples and pears but
once reporting mechanisms in both registries are
fully deciphered it will be interesting to see whether
existing differences influence implantation strat-
egies in both Europe and America [13,43
&&
]. These
differences should also be taken into account in
amalgamated data, such as the IMACS registry
(ISHLT mechanically assisted circulatory support
registry) [44].CONCLUSION
The VAD technology improved from generation to
generation remarkably leading to improved survival
and seemingly low morbidity, at the same time.
However, from the European point of view, updated
analysis of EUROMACS retrieves a different picture
with respect to mortality and morbidity. In fact, we
do have to accept in daily life the burden of serious
adverse events of about 65% during the first year of
bridging, which reinforces the incredible value of
HTx. We are sometimes faced by the statement that
the concept of HTx is futureless, which seems to be
for someone who treats and compares both patients
in daily practice questionable. Up to now, LVAD
therapy remains a bridge to a better future, which
means a bridge to technical innovations or to over-
come the dramatic lack of donors in Europe.
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